


## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Single Technology Appraisal**

# Obinutuzumab for treating lupus nephritis ID6420

## **Provisional Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	<u>General</u>
Roche (obinutuzumab)	<ul> <li>All Wales Therapeutics and Toxicology Centre</li> </ul>
Patient/carer groups	Allied Health Professionals Federation
Arthritis Action	Board of Community Health Councils in
Arthritis & Musculoskeletal Alliance	Wales
Genetic Alliance UK	British National Formulary
Gene People	Care Quality Commission
Hibbs Lupus Trust	Department of Health - Northern Ireland
Kidney Care UK	Healthcare Improvement Scotland
Lupus Trust	Medicines and Healthcare products
Lupus UK	Regulatory Agency
National Kidney Federation	National Association of Primary Care
National Rheumatoid Arthritis Society	National Pharmacy Association
Polycystic Kidney Disease Charity	NHS Confederation
South Asian Health Foundation	NHS England Specialised
Specialised Healthcare Alliance	Rheumatology Clinical Reference
	Group
Healthcare professional groups	Scottish Medicines Consortium
<ul> <li>Association of Renal Industries</li> </ul>	Welsh Government
<ul> <li>Association of Renal Technologists</li> </ul>	Welsh Health Specialised Services
British Association of Urological	Committee
Nurses	
British Association of Urological	Possible comparator companies
Surgeons	Aspen (azathioprine)
British Geriatrics Society	Astellas Pharma (tacrolimus)
British Isles Lupus Assessment Group	Baxter Healthcare (cyclophosphamide)
British Society for Allergy and Clinical	Chiesi (tacrolimus)
Immunology	Celltrion Healthcare (rituximab)
British Society for Haematology	Dexcel Pharm (ciclosporin)
British Society for Rheumatology	Leo Laboratories (tacrolimus)
British Society of Haemostasis and	Mylan (azathioprine, ciclosporin)
Thrombosis	Nova Laboratories (azathioprine)
Clinical Leaders of Thrombosis	Novartis (ciclosporin, mycophenolic
Primary Care Rheumatology Society	acid)
Royal College of General Practitioners	Otsuka Pharmaceuticals (voclosporin)
Royal College of Nursing	Pfizer (rituximab)
Royal College of Pathologists	



#### **Provisional Consultees Provisional Commentators (no right to** submit or appeal) Royal College of Physicians Roche (rituximab, mycophenolate Royal Pharmaceutical Society mofetil) Royal Society of Medicine **Rosemont Pharmaceuticals** (mycophenolate mofetil) Society for DGH Nephrologists Sandoz (cyclophosphamide, Society for Vascular Technology mycophenolic acid, rituximab, Society of Vascular Nurses tacrolimus) **UK Clinical Pharmacy Association** • Santen (ciclosporin) **UK Kidney Association** Strides Pharma (azathioprine) **UK Renal Pharmacy Group** Teva Pharma (mycophenolate mofetil) **United Kingdom Primary** • Tillomed Laboratories (azathioprine, Immunodeficiency Network mycophenolate mofetil) **Urology Foundation** Vascular Society of Great Britain and Relevant research groups Ireland Cochrane Kidney and Transplant Group **Genomics England** Others Kidney Research UK Department of Health and Social Care MRC Clinical Trials Unit NHS England National Institute for Health Research Associated Public Health groups **Public Health Wales UK Health Security Agency**

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### **Definitions:**


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of Obinutuzumab for treating lupus nephritis ID6420 Issue date: December 2024



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

## Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.